The data shown below were collected from the profiles of 60 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
|
|---|---|
| Published in |
Cancer Discovery, October 2023
|
| DOI | 10.1158/2159-8290.cd-23-0456 |
| Pubmed ID | |
| Authors |
Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Julia A. Sobotka, Precious Uju, Jenna Eagles, Stephanie Pedersen, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Lawrence E. Heisler, Richard Jovelin, Bernard Lam, Beatriz E. Lujan Toro, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, Carina Man, Anna Goldenberg, Wei Xu, Patrick Veit-Haibach, Andrea S. Doria, David Malkin, Raymond H. Kim, Trevor J. Pugh |
| Abstract |
People with Li-Fraumeni syndrome harbor a germline pathogenic variant in the TP53 tumor suppressor gene; face a near 100% lifetime risk of cancer; and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multi-modal liquid biopsy assay that integrates a targeted gene panel, shallow whole genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 Li-Fraumeni syndrome patients. Multi-modal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis; and was able to detect cancer-associated signal in carriers prior to diagnosis with conventional screening (PPV = 67.6%, NPV = 96.5%). While adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with Li-Fraumeni syndrome. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 9 | 15% |
| United States | 3 | 5% |
| France | 1 | 2% |
| Pakistan | 1 | 2% |
| United Kingdom | 1 | 2% |
| Unknown | 45 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 28 | 47% |
| Scientists | 25 | 42% |
| Practitioners (doctors, other healthcare professionals) | 6 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 16% |
| Other | 3 | 9% |
| Unspecified | 2 | 6% |
| Professor > Associate Professor | 2 | 6% |
| Student > Master | 2 | 6% |
| Other | 5 | 16% |
| Unknown | 13 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 16% |
| Medicine and Dentistry | 5 | 16% |
| Unspecified | 2 | 6% |
| Computer Science | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 15 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 112. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2024.
All research outputs
#391,270
of 26,096,076 outputs
Outputs from Cancer Discovery
#192
of 4,188 outputs
Outputs of similar age
#7,111
of 367,462 outputs
Outputs of similar age from Cancer Discovery
#12
of 110 outputs
Altmetric has tracked 26,096,076 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,188 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,462 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 110 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.